Fig. 4: In vivo experiments demonstrate that deficiency of miR-93 generates smaller heterotopic human pancreatic xenografts with a significant slower progression. | Oncogenesis

Fig. 4: In vivo experiments demonstrate that deficiency of miR-93 generates smaller heterotopic human pancreatic xenografts with a significant slower progression.

From: MiR-93 is related to poor prognosis in pancreatic cancer and promotes tumor progression by targeting microtubule dynamics

Fig. 4

a Tumor growth (%) measurement every two days, from day 8 after subcutaneous transplantation of PANC-1 control or KO-miR-93 cells into each flank of 6-weeks-old nude mice to day 42 (n = 14 tumors per group). b Tumor volume (mm3) 7 weeks postinjection and c tumor burden (g) 7 weeks postinjection. d Representative images of tumors at 7 weeks postinjection (n = 14 tumors per group). e Hematoxilin-eosin and Ki67 staining of fixed tumors; left: representative optical microscope images (n = 14), hematoxilin-eosin: magnitude 20×, scale bars: 50 µm, Ki67: magnitude 10×, scale bars:100 µm; right: tumor proliferation index, Ki67 positive cells with respect to total cells (n = 3) C1: clone1 and C2: clone 2. Error bars = s.d. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.

Back to article page